Tanhuo decoction

PreclinicalSmall molecule

Tanhuo decoction is one of 4 small molecule programs targeting Cerebral Atherosclerosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral AtherosclerosisActive, not recruiting

Cerebral AtherosclerosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Cerebral Atherosclerosis

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

1 2

Plavix

Sanofi

Approved

1 3

Bayer Aspirin

Tanhuo decoction

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ANot yet recruiting

Cerebral Atherosclerosis

NCT07445581

Clinical

Trials by Indication[1]

Cerebral Atherosclerosis1 trial

Tanhuo Decoction for Acute Coronary Syndrome With Cerebral Atherosclerosis in Elderly Patients

Not yet recruiting·JJinggang Xia, MD·N/A·NCT07445581·480 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tanhuo decoction. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tanhuo decoction compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tanhuo decoction. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jinggang Xia, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJinggang Xia, MD

Tanhuo decoction

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Cerebral Atherosclerosis1 trial

References

Drug Info

Quick Facts

Related News